The Immunology of DLBCL.
Taishi TakaharaShigeo NakamuraToyonori TsuzukiAkira SatouPublished in: Cancers (2023)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation. Recent next-generation sequencing studies have linked these interactions with the molecular classification of DLBCL. For example, germinal center B-cell-like DLBCL tends to show strong associations with follicular T cells and epigenetic regulation of immune recognition molecules, whereas activated B-cell-like DLBCL shows frequent genetic aberrations affecting the class I major histocompatibility complex. Single-cell technologies have also provided detailed information about cell-cell interactions and the cell composition of the microenvironment of DLBCL. Aging-related immunological deterioration, i.e., immunosenescence, also plays an important role in DLBCL pathogenesis, especially in Epstein-Barr virus-positive DLBCL. Moreover, DLBCL in "immune-privileged sites"-where multiple immune-modulating mechanisms exist-shows unique biological features, including frequent down-regulation of immune recognition molecules and an immune-tolerogenic tumor microenvironment. These advances in understanding the immunology of DLBCL may contribute to the development of novel therapies targeting immune systems.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- single cell
- rna seq
- cell therapy
- signaling pathway
- high throughput
- stem cells
- copy number
- machine learning
- induced apoptosis
- healthcare
- dendritic cells
- oxidative stress
- mesenchymal stem cells
- dna methylation
- bone marrow
- high grade
- low grade
- cell death
- health information
- social media